Company Quick10K Filing
Green Planet Bio Engineering
10-Q 2020-03-31 Filed 2020-05-15
10-K 2019-12-31 Filed 2020-03-11
10-Q 2019-09-30 Filed 2019-11-08
10-Q 2019-06-30 Filed 2019-08-12
10-Q 2019-03-31 Filed 2019-05-08
10-K 2018-12-31 Filed 2019-03-01
10-Q 2018-09-30 Filed 2018-11-14
10-Q 2018-06-30 Filed 2018-08-10
10-Q 2018-03-31 Filed 2018-05-11
10-K 2017-12-31 Filed 2018-03-08
10-Q 2017-09-30 Filed 2017-10-27
10-Q 2017-06-30 Filed 2017-08-04
10-Q 2017-03-31 Filed 2017-05-15
10-K 2016-12-31 Filed 2017-03-10
10-Q 2016-09-30 Filed 2016-11-04
10-Q 2016-06-30 Filed 2016-08-09
10-Q 2016-03-31 Filed 2016-05-13
10-K 2015-12-31 Filed 2016-03-30
10-Q 2015-09-30 Filed 2015-11-16
10-Q 2015-06-30 Filed 2015-08-11
10-Q 2015-03-31 Filed 2015-05-14
10-K 2014-12-31 Filed 2015-03-31
10-Q 2014-09-30 Filed 2014-11-14
10-Q 2014-06-30 Filed 2014-08-15
10-Q 2014-03-31 Filed 2014-05-15
10-K 2013-12-31 Filed 2014-04-15
10-Q 2013-09-30 Filed 2013-11-14
10-Q 2013-06-30 Filed 2013-08-16
10-Q 2013-03-31 Filed 2013-05-20
10-K 2012-12-31 Filed 2013-04-16
10-Q 2012-09-30 Filed 2012-11-14
10-Q 2012-06-30 Filed 2012-08-20
10-Q 2012-03-31 Filed 2012-05-14
10-K 2011-12-30 Filed 2012-04-03
10-Q 2011-09-30 Filed 2011-11-21
10-Q 2011-06-30 Filed 2011-08-15
10-Q 2011-03-31 Filed 2011-05-16
10-K 2010-12-31 Filed 2011-04-14
10-Q 2010-09-30 Filed 2010-11-10
10-Q 2010-06-30 Filed 2010-08-23
10-Q 2010-03-31 Filed 2010-05-17
10-K 2009-12-31 Filed 2010-03-30
8-K 2019-12-18

GPLB 10Q Quarterly Report

EX-31.1 gplb_ex31.htm
EX-32.1 gplb_ex32.htm

Green Planet Bio Engineering Earnings 2020-03-31

Balance SheetIncome StatementCash Flow

10-Q 1 gplb_10q.htm QUARTERLY REPORT gplb_10q
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
_______________________
 
FORM 10-Q
_______________________
(Mark One)
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the quarterly period ended March 31, 2020
 
or
 
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
 
For the transition period from___________ to ____________
      
Commission file number 000-52622
 
GREEN PLANET BIOENGINEERING CO., LTD.
(Exact Name of Registrant as Specified in its charter)
 
 Delaware
 37-1532842
 (State or other jurisdiction of incorporation or organization)
 (I.R.S. Employer Identification No.)
 
 20807 Biscayne Blvd., Suite 203, Aventura, Florida
 33180
 (Address of principal executive offices)
 (Zip Code)

(786) 279-2900
(Registrant’s telephone number, including area code)
 
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes ☒    No ☐
 
Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
 
Large accelerated filer
 
Accelerated filer
 
Non-accelerated filer
 
Smaller reporting company
 
 
 
(Do not check if a smaller company)
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act) Yes ☒  No  ☐
 
 
The number of shares of common stock outstanding as of May 13, 2020 was 20,006,402.
 

 
 
 
TABLE OF CONTENTS
 
Page Number
 
 
 
Financial Statements
1




Balance Sheets as of March 31, 2020 (Unaudited) and December 31, 2019
1




Statements of Operations for the Three Months Ended March 31, 2020 and 2019 (Unaudited)
2



 
Statements of Stockholders’ Deficit for the Three Months Ended March 31, 2020 and 2019 (Unaudited)
3
 
 
 
 
Statements of Cash Flows for the Three Months Ended March 31, 2020 and 2019  (Unaudited)
 4
 
 
 
 
Notes to the Financial Statements 
 5
 
 
 
Management’s Discussion and Analysis of Financial Condition and Results of Operations 
 7
 
 
 
Quantitative and Qualitative Disclosures about Market Risk 
 8
 
 
 
Controls and Procedures 
 8
 
 
 
 
 
 
 
Item 1.
Legal Proceedings
9



Item 2.
Unregistered Sales of Equity Securities and Use of Proceeds
9



Item 3.
Defaults upon Senior Securities
9



Item 4.
Reserved
9



Item 5.
Other Information
9


 
Item 6.
Exhibits
 9

 
 
SIGNATURES  
 10
 
 
 
 
INTERIM FINANCIAL STATEMENTS
 
The unaudited interim financial statements have been prepared in accordance with generally accepted accounting principles in the United States for interim financial information and with the instructions under Regulation S-X of the Securities and Exchange Commission (“SEC”) Form 10-Q. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. Therefore, these financial statements should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended December 31, 2019.
 
The financial statements included herein are unaudited; however, they contain all normal recurring accruals and adjustments that, in the opinion of management, are necessary to present fairly the Company’s financial position as of the period reporting date, and the results of its operations and cash flows for the fiscal period end. The results of operations for the fiscal period end are not necessarily indicative of the results to be expected for future quarters or the full fiscal year.
 
 
 FORWARD-LOOKING STATEMENTS
 
This Quarterly Report on Form 10-Q contains forward-looking statements. These statements involve risks and uncertainties, including, among other things, statements regarding our business strategy, future revenues and anticipated costs and expenses. Such forward-looking statements include, among others, those statements including the words “expects,” “anticipates,” “intends,” “believes,” “may,” “will,” “should,” “could,” “plans,” “estimates,” and similar language or negative of such terms. Our actual results may differ significantly from those projected in the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, those discussed in Item 2 “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this report. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we do not know whether we can achieve positive future results, levels of activity, performance, or goals. Actual events or results may differ materially. We undertake no obligation to publicly release any revisions to the forward-looking statements or reflect events or circumstances taking place after the date of this document.
 
 
 
 
PART I 
FINANCIAL INFORMATION
 
ITEM 1. 
FINANCIAL STATEMENTS
 
 
Green Planet Bioengineering Co., Ltd.
Condensed Balance Sheets
 
 
 
March 31,
 
 
December 31,
 
 
 
2020
 
 
2019
 
 
 
(Unaudited)
 
 
 
 
ASSETS
 
 
 
 
 
 
Current assets
 
 
 
 
 
 
Cash and cash equivalents
 $- 
 $- 
 
    
    
TOTAL CURRENT ASSETS
 $- 
 $- 
 
    
    
LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
    
    
 
    
    
LIABILITIES
    
    
Current liabilities
    
    
Accounts payable
 $- 
 $214 
Accrued liabilities
  - 
  - 
Amount due to a related party
  297,199 
  282,645 
 
    
    
TOTAL CURRENT LIABILITIES
  297,199 
  282,859 
 
    
    
Commitments and Contingencies (see note 7)
  - 
  - 
 
    
    
STOCKHOLDERS’ (DEFICIT)
    
    
Preferred stock : par value of $0.001 per share,
    
    
Authorized: 10,000,000 shares at March 31, 2020 and December 31, 2019
    
    
Issued and outstanding : 0 shares at March 31, 2020 and December 31, 2019
  - 
  - 
 
    
    
Common stock : par value $0.001 per share
    
    
Authorized : 250,000,000 shares at March 31, 2020 and December 31, 2019
    
    
Issued and outstanding : 20,006,402 shares at March 31, 2020 and December 31, 2019
  20,006 
  20,006 
Additional paid-in capital
  609,614 
  609,614 
Accumulated (deficit)
 $(926,819)
 $(912,479)
 
    
    
TOTAL STOCKHOLDERS’ (DEFICIT)
 $(297,199)
 $(282,859)
 
    
    
TOTAL LIABILITIES AND STOCKHOLDERS’ (DEFICIT)
 $- 
 $- 
 
See Notes to the Unaudited Condensed Financial Statements
 
 
1
 
 
Green Planet Bioengineering Co., Ltd.
Condensed Statements of Operations
(Unaudited)
 
 
 
Three months ended March 31,
 
 
 
2020
 
 
2019
 
 
 
 
 
 
 
 
Administrative expenses
 $(14,340)
 $(8,119)
 
    
    
Loss before income taxes
  (14,340)
  (8,119)
Provision for income taxes
  - 
  - 
 
    
    
Net loss
 $(14,340)
 $(8,119)
 
    
    
Earnings per share
    
    
- Basic and diluted
 $(0)*
 $(0)*
 
    
    
Weighted average number of shares outstanding:
    
    
- Basic and diluted
  20,006,402 
  20,006,402 
 
* Less than $.01, per share
 
See Notes to the Unaudited Condensed Financial Statements
 
 
2
 
 
Green Planet Bioengineering Co., Ltd
Condensed Statements of Changes in Stockholders’ Deficit
For the Three Months Ended March 31, 2020 and 2019
(Unaudited)
 
 
 
Preferred Stock
 
 
Common Stock
 
   
   
   
 
 
Number of Shares
 
 
Amount
 
 
Number of Shares
 
 
Amount
 
 
Additional paid-in capital
 
 
Accumulated deficit
 
 
Total
 
Balance, December 31, 2018
  - 
 $- 
  20,006,402 
 $20,006 
 $609,614 
 $(887,121)
 $(257,501)
 
    
    
    
    
    
    
    
Net loss
  - 
  - 
  - 
  - 
  - 
  (8,119)
  (8,119)
 
    
    
    
    
    
    
    
Balance, March 31, 2019 (Unaudited)
  - 
 $- 
  20,006,402 
 $20,006 
 $609,614 
 $(895,240)
 $(265,260)
 
    
    
    
    
    
    
    
  
    
    
    
    
    
    
    
Balance, December 31, 2019  
  - 
 $- 
  20,006,402 
 $20,006 
 $609,614 
 $(912,479)
 $(282,859)
 
    
    
    
    
    
    
    
Net loss
  - 
  - 
  - 
  - 
  - 
 $(14,340)
 $(14,340)
 
    
    
    
    
    
    
    
Balance, March 31, 2020 (Unaudited)
  - 
 $- 
  20,006,402 
 $20,006 
 $609,614 
 $(926,819)
 $(297,199)
 
See Notes to the Unaudited Condensed Financial Statements
 
 
3
 
 
Green Planet Bioengineering Co., Ltd.
Condensed Statements of Cash Flows
(Unaudited)
 
 
 
  Three months ended March 31,
 
 
 
2020
 
 
2019
 
Cash flows from operating activities
 
 
 
 
 
 
Net loss
 $(14,340)
 $(8,119)
Changes in operating assets and liabilities:
Accounts payables
  (214)
  - 
Accrued liabilities
  - 
  (3,250)
Net cash flows used in operating activities
  (14,554)
  (11,369)
 
    
    
Cash flows from investing activities
  - 
  - 
 
    
    
Cash flows from financing activities
    
    
Amount due to a related company
  14,554 
  11,369 
 
    
    
Cash flows from financing activities
  14,554 
  11,369 
 
    
    
Net decrease in cash and cash equivalents
  - 
  - 
    Cash and cash equivalents - beginning of period
  - 
  - 
 
    
    
  Cash and cash equivalents - end of period
 $- 
 $- 
 
    
    
Supplemental disclosures for cash flow information:
    
    
Cash paid for interest
 $- 
 $- 
Cash paid for income taxes
 $- 
 $- 
 
See Notes to the Unaudited Condensed Financial Statements
 
 
4
 
 
Green Planet Bioengineering Co., Ltd
Notes to the Condensed Financial Statements
(Unaudited)
 
1. General Information
 
Mondo Acquisition II, Inc. was incorporated in the State of Delaware on October 30, 2006 and the name was changed to Green Planet Bioengineering Co., Ltd. (“Company”) on October 2, 2008. In October 2008, the Company acquired Elevated Throne Overseas Ltd, incorporated in British Virgin Islands, and its subsidiaries which was subsequently divested to One Bio, Corp (“ONE”) on April 14, 2010.
 
In March 2012, the Company became a subsidiary of Global Fund Holdings Corp. (“Global Funds”) an Ontario, Canada Corporation.
 
The Company operates as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation. The Company's activities are subject to significant risks and uncertainties, as their ability to implement and execute future business plans and generate sufficient business revenue is directly influenced by their ability to secure adequate financing or find profitable business opportunities.
 
2. Summary of significant accounting policies
 
Basis of Presentation
The accompanying unaudited interim consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles for interim financial information and with the instructions to Form 10- Q of Regulation S-K. They may not include all information and footnotes required by United States generally accepted accounting principles for complete financial statements. However, except as disclosed herein, there have been no material changes in the information disclosed in the notes to the financial statements for the year ended December 31, 2019 included in the Company’s Annual Report on Form 10-K filed with the United States Securities and Exchange Commission. The unaudited interim consolidated financial statements should be read in conjunction with those financial statements included in the Form 10-K. In the opinion of management, all adjustments considered necessary for a fair presentation, consisting solely of normal and recurring adjustments have been made. Operating results for the three months ended March 31, 2020 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2020.
 
Use of Estimates
The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses for the years reported. Actual results could differ from those estimates. Significant items that require estimates were accruals of liabilities.
 
Cash and cash equivalents
Cash and cash equivalents include all cash, deposits in banks and other highly liquid investments with initial maturities of three months or less to be cash equivalents. Balances of cash and cash equivalents in financial institutions may at times exceed the government-insured limits.
 
Earnings per share
Earnings per share is reported in accordance with FASB ASC Topic 260 “Earnings per Share” which requires dual presentation of basic earnings per share (“EPS”) and diluted EPS on the face of all statements of earnings, for all entities with complex capital structures. Diluted EPS reflects the potential dilution that could occur from common shares issuable through the exercise or conversion of stock options, restricted stock awards, warrants and convertible securities. In certain circumstances, the conversion of these options, warrants and convertible securities are excluded from diluted EPS if the effect of such inclusion would be anti-dilutive. Fully diluted EPS is not provided, when the effect is anti-dilutive. When the effect of dilution on loss per share is anti-dilutive, diluted loss per share equals the loss per share.
 
Fair Value Measurements
FASB ASC Topic 820, “Fair Value Measurements and Disclosures” defines fair value, establishes a framework for measuring fair value in accordance with U.S. GAAP, and expands disclosures about fair value measurements. Investment measured and reported at fair value are classified and disclosed in one of the following hierarchy:
 
Level 1 - Quoted prices are available in active markets for identical investments as of the period reporting date
 
Level 2 - Pricing inputs are other than quoted prices in active markets, which are either directly or indirectly observable as of the reporting date, and fair value is determined through the use of models or other valuation methodologies.
 
Level 3 - Pricing inputs are unobservable for the investment and included situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require significant management judgment or estimation.
 
 
5
 
 
2. Summary of Significant Accounting Policies – continued
 
Recent Changes in Accounting Standards
In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement. The standard will modify the disclosure requirements for fair value measurements by removing, modifying, or adding certain disclosures. ASU No. 2018-13 is effective for annual reporting periods beginning after December 15, 2019, including interim periods within that reporting period. Early adoption is permitted upon issuance of this ASU. The Company is permitted to early adopt any removed or modified disclosures upon issuance of this ASU and delay adoption of the additional disclosures until their effective date. The adoption of this ASU did not have a material impact on the Company’s condensed financial statements.
 
In June 2018, the FASB issued ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting”, which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. The changes take effect for public companies for fiscal years starting after December 15, 2018, including the interim periods within that fiscal year. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2019, and interim periods within fiscal years beginning after December 15, 2020. The adoption of this ASU did not have a material impact on the Company’s financial statements.
 
Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the accompanying financial statements.
 
Reclassifications
Certain accounts in the 2020 condensed financial statements have been reclassified to conform with current financial statements presentation.
 
3. Going Concern
 
The financial statements have been prepared assuming that the Company will continue as a going concern. The Company is currently a public reorganized shell corporation and has no current business activity. The Company’s ability to continue as a going concern is dependent on continued support from Global Funds, the majority stockholder. This gives rise to substantial doubt about the Company’s ability to continue as a going concern.
 
4. Amount Due to a Related Company
 
The Company relies on a related company to advance funds to finance its operating expenses. The amounts advanced of $297,199 are interest-free, unsecured and are repayable upon demand.
 
5. Preferred stock / Common stock
 
Series A Preferred stock
The Company is authorized under its Articles of Incorporation to issue 10,000,000 shares of Series A preferred stock with a par value of $0.001 per share. Each share of the Company’s preferred stock provides the holder with the right to vote 1,000 votes on all matters submitted to a vote of the stockholders of the Company and is convertible into 1,000 shares of the Company’s common stock. The preferred stock is non-participating and carries no dividend.
 
The Company does not have any issued shares of the preferred stock as of March 31, 2020 and December 31, 2019.
 
Common stock
The Company is authorized to issue 250,000,000 shares of common stock with a par value of $0.001 per share. During the three months ended March 31, 2020, the Company did not issue any shares of common stock or warrants.
 
6. Stock-based compensation
 
There was no non-cash stock-based compensation recognized for the three months ended March 31, 2020 and 2019.
 
7. Commitments and Contingencies
 
The Company’s operation has not been materially and adversely impacted by the Covid-19 pandemic. The Company is located in Florida which is subject to a “stay at home” order effective April 3, 2020. While the Company is able to continue operations as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation that can operate with some of the staff working from home and minimal staff at the office as long as they maintain social distancing. Until this stay at home order is lifted the Company will continue to follow social distancing order. The Company is unable to predict the impact of the Covid-19 pandemic at this time.
 
 
6
 
 
ITEM 2.
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
 
General Overview
 
The Company operates as a public reorganized corporation with the business purpose to acquire or merge with an existing business operation.
 
Results of Operations and Financial Condition for the three months ended March 31, 2020, as compared to the three months ended March 31, 2019
 
The Company had no active business operations for the periods ended March 31, 2020 and March 31, 2019. Expenses consist of accounting and filing fees.
 
Liquidity and capital resources
 
The Company had no active business operations for the three months ended March 31, 2020 and 2019. Accordingly, all the Company’s cash flow needs were provided by a related company.
 
Risk factors
 
The Company’s critical accounting policies are still being applied despite the fact that the Company has no ongoing business operations.
 
The Company’s operation has not been materially and adversely impacted by the Covid-19 pandemic. The Company is located in Florida which is subject to a “stay at home” order effective April 3, 2020. While the Company is able to continue operations as a public reorganized shell corporation with the purpose to acquire or merge with an existing business operation that can operate with some of the staff working from home and minimal staff at the office as long as they maintain social distancing. Until this stay at home order is lifted the Company will continue to follow social distancing order. The Company is unable to predict the impact of the Covid-19 pandemic at this time.
 
Significant Estimates
 
The preparation of financial statements in conformity with generally accepted accounting principles in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, as well as the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.
 
Critical Accounting Policies
 
We prepare our financial statements in conformity with generally accepted accounting principles in the United States of America. As such, we are required to make certain estimates, judgments and assumptions that we believe are reasonable based upon historical experience, current trends and other factors. These estimates, judgments and assumptions affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the periods presented. Actual results could be different than those estimates.
 
Off-Balance Sheet Arrangements
 
We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.
 
Market Risks
 
There has been no material change in market risks since our last Annual Report on Form 10-K for the year ended December 31, 2019.
 
 
7
 
 
ITEM 3.
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
 
None
 
ITEM 4. 
CONTROLS AND PROCEDURES
 
Evaluation of Disclosure Controls and Procedures
 
Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 under the Securities Exchange Act of 1934, as amended (Exchange Act), as of the end of the period covered by this Quarterly Report on Form 10-Q.
 
Based on this evaluation, our chief executive officer and chief financial officer concluded that, as of the fiscal period end, our disclosure controls and procedures are designed at a reasonable assurance level and are effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure.
 
Changes in Internal Control over Financial Reporting
 
There were no changes in our internal control over financial reporting that occurred during the quarter ended March 31, 2020 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
 
Limitations on Effectiveness of Controls and Procedures
 
In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply its judgment in evaluating the benefits of possible controls and procedures relative to their costs.
 
 
8
 
 
PART II
OTHER INFORMATION
 
ITEM 1.
LEGAL PROCEEDINGS
 
None
 
ITEM 2. 
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
 
None
 
ITEM 3. 
DEFAULTS UPON SENIOR SECURITIES
 
None
 
ITEM 4. 
RESERVED
 
ITEM 5. 
OTHER INFORMATION
 
None
 
ITEM 6. 
EXHIBITS
 
31         Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32         Certification of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350
 
 
9
 
 
SIGNATURES
 
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned; thereunto duly authorized this 13th day of May, 2020.
 
 
GREEN PLANET BIOENGINEERING CO., LTD.
 
 
 
 
 
Date: May 13, 2020
By:  
/s/ Jordan Weingarten  
 
 
 
Jordan Weingarten  
 
 
 
President (Principal Executive Officer
and Principal Financial and Accounting
Officer) and Director
 
 
 
 
10